Product Name:Methyl 4-formylbenzoate

IUPAC Name:methyl 4-formylbenzoate

CAS:1571-08-0
Molecular Formula:C9H8O3
Purity:95%+
Catalog Number:CM157703
Molecular Weight:164.16

Packing Unit Available Stock Price($) Quantity
CM157703-1000g in stock ƄNJ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1571-08-0
Molecular Formula:C9H8O3
Melting Point:-
Smiles Code:C1=C(C(OC)=O)C=CC(=C1)C=O
Density:
Catalog Number:CM157703
Molecular Weight:164.16
Boiling Point:265°C at 760 mmHg
MDL No:MFCD00006950
Storage:Keep in Inert atmosphere, store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Risvodetinib
Inhibikase Therapeutics’s Risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. FDA for the treatment of Multiple System Atrophy (MSA). MSA is a rapidly progressive rare condition of the nervous system that causes gradual damage to nerve cells in the brain, and shares many symptoms with Parkinson's disease. This neurological disorder has an estimate an average of 0.6 to 0.7 new cases per 100,000 people yearly.
The non-receptor tyrosine kinase Abelson, c-Abl is shown to be implicated in the initiation and progression of α-synuclein (α-syn) pathogenesis and neurodegeneration. Risvodetinib is a brain-penetrant selective inhibitor of c-Abl1 and Abl2 undergoing Phase 2 clinical studies.